Introduction Patients with non-small cell lung cancer (NSCLC) harboring uncommon
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …

Purpose: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R,
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …

Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …

Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous
subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations …

Background The significance of uncommon EGFR mutations in newly diagnosed advanced
non-small-cell lung cancer (NSCLC) patients is incompletely known. We aimed to analyze …

Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …

Background Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-
cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study …

Background EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease.
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …

The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …

Introduction There are a number of uncommon EGFR mutations whose associations with
TKIs are not well clarified. Here, we summarize the clinical data of patients with multiple …